Key facts
- Nyctea Technologies’s last known valuation is $5.7M (Nov 2024).
- It has raised $1.6M; the latest was Seed Round ($630K) in Sep 2025.
- Notable investors include MedTech Innovator, Chalmers Ventures, Chalmers University of Technology.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Nyctea Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Nyctea Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nyctea Technologies
Developer of a purification technology company designed for biopharmaceutical and protein production. The company's technology manufactures biomolecule purification systems for discovering the biomolecule trapping functionalities of sense and act polymer electrodes, enabling researchers to develop new drugs and treatments at a cheap rate.
- Sector
- Healthcare
- HQ
- Gothenburg, Sweden
- Founded
- 2020
- Employees
- 10
- Website
- nycteatechnologies.com/
- Ownership
- Privately Held (backing)
Nyctea Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nyctea Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nyctea Technologies in its N-PORT filings yet. We sweep new filings monthly.